<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893630</url>
  </required_header>
  <id_info>
    <org_study_id>47841</org_study_id>
    <nct_id>NCT03893630</nct_id>
  </id_info>
  <brief_title>Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia</brief_title>
  <acronym>ASPERIN</acronym>
  <official_title>Role of Aspirin in Maternal Endothelial Dysfunction and Uterine Artery Blood Flow in Women at Risk for Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John O'Brien, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelial dysfunction and defective placental vascularization are hypothesized to be&#xD;
      significant causes of preeclampsia. In preeclampsia, due to vascular endothelial dysfunction,&#xD;
      vasoconstriction and platelet activation can result in severe features which alter pregnancy&#xD;
      outcomes. However, studies have shown that acetylsalicylic acid (Aspirin) can decrease&#xD;
      endothelial dysfunction leading to decreased platelet aggregation which reduces adverse&#xD;
      outcomes. The objective of our study is to determine if Aspirin has a dose-dependent response&#xD;
      for modifying biomarkers reflective of maternal endothelial dysfunction when indicated for&#xD;
      preeclampsia prevention in a cohort of women identified at risk for developing preeclampsia.&#xD;
&#xD;
      Pregnant women who are at risk for preeclampsia will be randomized to receive either 81mg&#xD;
      Aspirin or 162mg Aspirin daily starting from 11-16 weeks of gestation until 36 weeks of&#xD;
      gestation. A third, control group of women at low risk for preeclampsia will not receive&#xD;
      aspirin. All women will be assessed with uterine artery Doppler studies and mean arterial&#xD;
      blood pressures at three time points during pregnancy. Blood, urine, and cord blood samples&#xD;
      will also be collected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible women will be identified in the late first or early second trimesters. Once&#xD;
      recruited, women will be randomly assigned to either 81 mg or 162 mg per day dosing&#xD;
      schedules. The randomization scheme will vary based on the body mass index (BMI) with&#xD;
      separate schemes for women &lt;=30 kg/m2 versus &gt;30 kg/m2. Ultrasonographic assessment of&#xD;
      biophysical biomarkers will be obtained at 11-16 weeks, 18-22 weeks, and 28-32 weeks&#xD;
      gestation. Biologic samples of serum and urine will be obtained at the 11-16 week and 28-32&#xD;
      week visit. Upon delivery, cord blood and a placental specimen will also be obtained.&#xD;
      Medication treatment will continue until 36 weeks gestation. Pregnancy and neonatal outcome&#xD;
      data will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pulsatility Index (PI)</measure>
    <time_frame>Three times between 11 and 32 weeks of gestation.</time_frame>
    <description>Uterine artery doppler will be used to assess impedance to flow in the uterine artery three times: at 11-16 weeks gestation, 18-22 weeks gestation, and 28-32 weeks gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of Pre-eclampsia</measure>
    <time_frame>Throughout pregnancy and postpartum ( 6 weeks after delivery)</time_frame>
    <description>Frequency of Disease during pregnancy and postpartum as defined by American College of Obstetrics and Gynecology (ACOG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Pre-eclampsia</measure>
    <time_frame>Throughout pregnancy and immediate postpartum ( 6 weeks after delivery)</time_frame>
    <description>Frequency women are identified with Severe Features of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Neonatal outcomes including frequency of Intraventricular hemorrhage (IVH), Bronchopulmonary dysplasia (BPD), Respiratory distress syndrome (RDS), Necrotising enterocolitis(NEC)</measure>
    <time_frame>Neonatal period ( first 28 days after birth)</time_frame>
    <description>Frequency of adverse neonatal outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in s-ICAM levels over time</measure>
    <time_frame>Three times between 11 and 32 weeks of gestation</time_frame>
    <description>Serial biologic samples will be obtained in the first, second, and third trimesters to measure changes in soluble Intercellular Adhesion Molecule (s-ICAM) levels over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PIGF levels over time</measure>
    <time_frame>Three times between 11 and 32 weeks of gestation</time_frame>
    <description>Serial biologic samples will be obtained in the first, second, and third trimesters to measure changes in placental growth factor (PIGF) levels over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP levels over time</measure>
    <time_frame>Three times between 11 and 32 weeks of gestation</time_frame>
    <description>Serial biologic samples will be obtained in the first, second, and third trimesters to measure changes in C-reactive protein (CRP) levels over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IL-6 over time</measure>
    <time_frame>Three times between 11 and 32 weeks of gestation</time_frame>
    <description>Serial biologic samples will be obtained in the first, second, and third trimesters to measure changes in interleukin 6 (IL-6) levels over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TNF over time</measure>
    <time_frame>Three times between 11 and 32 weeks of gestation</time_frame>
    <description>Serial biologic samples will be obtained in the first, second, and third trimesters to measure changes in tumor necrosis factor (TNFα) levels over time.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic Acid 81mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive low dose (81mg) acetylsalicylic acid (Aspirin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic Acid 162mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive low dose (162mg) acetylsalicylic acid (Aspirin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic Acid 81 mg</intervention_name>
    <description>Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.</description>
    <arm_group_label>Acetylsalicylic Acid 81mg</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic Acid 162 mg</intervention_name>
    <description>Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.</description>
    <arm_group_label>Acetylsalicylic Acid 162mg</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (control)&#xD;
&#xD;
        • No risk factors for preeclampsia&#xD;
&#xD;
        Inclusion Criteria (pre-eclampsia)&#xD;
&#xD;
          -  History of preterm preeclampsia&#xD;
&#xD;
          -  Chronic hypertension&#xD;
&#xD;
          -  Type 1 and Type 2 diabetes&#xD;
&#xD;
          -  Renal diseases&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pregnant women younger than 18 years or older than 45 years&#xD;
&#xD;
          -  Multiple gestations&#xD;
&#xD;
          -  History of allergy (urticaria or anaphylaxis) to aspirin or aspirin-related products&#xD;
             asthma that worsens after aspirin use&#xD;
&#xD;
          -  Patients with gastrointestinal or genitourinary bleeding&#xD;
&#xD;
          -  Patients with peptic ulcer disease&#xD;
&#xD;
          -  Patients with severe liver dysfunction&#xD;
&#xD;
          -  Patients who have undergone bypass surgery&#xD;
&#xD;
          -  Patients on anticoagulant medication(s)&#xD;
&#xD;
          -  Women with anomalous fetus&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M O'Brien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katherine Vignes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aarthi Srinivasan, MD, MS</last_name>
    <phone>8592180765</phone>
    <email>asr224@uky.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia T Cockerham, BSN</last_name>
    <email>ctcock2@uky.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M O'Brien, MD</last_name>
      <phone>859-218-0765</phone>
      <email>john.obrien2@uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Cockerham, BSN</last_name>
      <email>ctcock2@uky.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine Vignes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robin Shoemaker, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aarthi Srinivasan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017 Aug 17;377(7):613-622. doi: 10.1056/NEJMoa1704559. Epub 2017 Jun 28.</citation>
    <PMID>28657417</PMID>
  </reference>
  <reference>
    <citation>Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007 May 26;369(9575):1791-1798. doi: 10.1016/S0140-6736(07)60712-0. Review.</citation>
    <PMID>17512048</PMID>
  </reference>
  <reference>
    <citation>Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018 Mar;218(3):287-293.e1. doi: 10.1016/j.ajog.2017.11.561. Epub 2017 Nov 11. Review.</citation>
    <PMID>29138036</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>John O'Brien, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>pulsatility index</keyword>
  <keyword>doppler</keyword>
  <keyword>uterine</keyword>
  <keyword>acetylsalicylic acid</keyword>
  <keyword>preeclampsia</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

